BridgeBio Pharma (BBIO) Short-term Investments (2019 - 2026)

BridgeBio Pharma has reported Short-term Investments for 8 years, with the latest figure at $60.3 million in Q1 2026.

• Quarterly Short-term Investments changed N/A year-over-year to $60.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $60.3 million (changed N/A YoY) and the FY2025 annual result came in at $17.4 million, changed N/A from the prior year.
• Short-term Investments rose to $60.3 million in Q1 2026 per BBIO's latest filing, from $17.4 million in the prior quarter.
• Over five years, Short-term Investments peaked at $139.4 million in Q2 2024 and troughed at $131000.0 in Q1 2024.
• A 5-year average of $35.5 million and a median of $30.9 million in 2023 frame the typical range for Short-term Investments.
• The sharpest annual moves came in 2022 and 2024: Short-term Investments jumped 21329.38% in 2022, then plunged 99.74% in 2024.
• Over 5 years, Short-term Investments stood at $37.9 million in 2022, then slumped by 56.1% to $16.7 million in 2023, then soared by 737.14% to $139.4 million in 2024, then tumbled by 87.55% to $17.4 million in 2025, then surged by 247.26% to $60.3 million in 2026.
• According to Business Quant data, Short-term Investments over the past three periods registered $60.3 million, $17.4 million, and $3.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.